U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
MARCH 30, 2000
------------------------------
(Date of earliest event reported)
AUTOLOGOUS WOUND THERAPY, INC.
------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-28443 23-2958959
------------------- ----------------- --------------------
(State of other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification Number)
1523 BOWMAN ROAD, SUITE A, LITTLE ROCK, ARKANSAS 72211
------------------------------------------------------------
(Address of principal executive offices)
501-225-8400
------------------
(Registrant's telephone number, including area code)
ITEM 5. OTHER EVENTS
On March 30, 2000, Autologous Wound Therapy, Inc. filed
a Certificate of Amendment to its Articles of Incorporation
changing the name of the Company to Cytomedix, Inc. The
action was approved by shareholder consent by written action
in lieu of a meeting by shareholders representing more than
fifty percent (50%) of the Company s issued and outstanding
voting common stock. The decision to change the name to
Cytomedix more accurately reflects management's intention to
<PAGE>
pursue a broader range of opportunities in cellular therapy
and molecular biotechnology markets, beyond the Company's
existing autologous treatments for nonhealing chronic
wounds.
The Company also completed the private placement of its
common stock previously announced March 9, 2000, to thirty-
one accredited investors. The offering raised $7,715,000 in
gross proceeds for the Company to be used for working
capital and general corporate purposes. The issue price of
the common stock in the private placement was $10.00 per
share. In connection with the offering, the Company paid
investment advisory fees of $212,000 and issued stock options
to acquire 26,500 at an exercise price of $10.00 per share
to The Kriegsman Group for services in connection with the
equity placement.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS
(c) Exhibits
Exhibit 2.4 Certificate of Amendment to Certificate
of Incorporation
Exhibit 99.1 Press release of the Company dated
April 4, 2000.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunder duly
authorized.
AUTOLOGOUS WOUND THERAPY, INC.
---------------------------------------------------------
(Registrant)
By: /s/ Dennis G. Hendren
----------------------------
Dennis G. Hendren, President
& CEO
Date: April 4, 2000
2
<PAGE>
Exhibit 2.4 - Certificate of Amendment to Certificate of Incorporation
STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 010:00 AM 3/30/2000
001161654 - 28900868
CERTIFICATE OF AMENDMENT
TO
CERTIFICATE OF INCORPORATION
OF
AUTOLOGOUS WOUND THERAPY, INC.
Under Section 242
of the General Corporation Law
of the State of Delaware
Autologous Wound Therapy, Inc., a Delaware corporation
(the "Company"), formerly known as Informatix Holdings,
Inc., hereby certifies as follows:
FIRST, Article 1 of the Certificate of Incorporation is
amended to read in its entirety as follows:
1. The name of the Corporation is
Cytomedix, Inc.
SECOND, this Certificate has been duly adopted in
accordance with the provisions of Section 242 of the General
Corporation Law of the State of Delaware.
IN WITNESS WHEREOF, Autologous Wound Therapy, Inc., has
caused this Certificate to be signed by William L. Brown,
its Secretary, this 27 day of March, 2000.
AUTOLOGOUS WOUND THERAPY, INC.
By: /s/ William L. Brown
___________________________
William L. Brown, Secretary
3
<PAGE>
Exhibit 99.1 Press Release of the Company dated April 4, 2000.
AUTOLOGOUS WOUND THERAPY, INC.
NAME CHANGED TO
CYTOMEDIX, INC.
FOR IMMEDIATE RELEASE
Little Rock, Arkansas April 4, 2000
Autologous Wound Therapy, Inc. ("AWTX") has changed its
name. The company filed an amendment of its certificate of
incorporation with the Delaware Secretary of State, adopting
the new name of Cytomedix, Inc. effective March 30, 2000.
Shareholders holding more than the ownership interests
required to approve the name change did so by consent action
in lieu of a meeting dated March 29, 2000.
In connection with the name change, the ticker symbol for
the company's stock will be changed and a new symbol will be
announced shortly.
The decision to change the name to Cytomedix more accurately
reflects management s intention to pursue a broader range of
opportunities in cellular therapy and molecular biotechnology
markets, beyond the company's existing activities in
autologous treatments for non-healing diabetic neuropathies,
and venous stasis and decubitus ulcers.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward looking statements involve known and
unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of
Cytomedix, Inc. (the Company ), or industry results, to be
materially different from any future results, performance
or achievements expressed or implied by such forward-looking
statements.
Readers of this press release may obtain additional
information on the Company in reports and other information
filed in accordance with the Securities Exchange Act of
1934, as amended (the "Exchange Act"). Such reports and
other information filed by the Company can be inspected and
copied at the public referenced facilities maintained by the
Commission at the Public Reference Room, 450 5th Street,
N.W., Washington, D.C. 20549. Copies of such material can
also be obtained at prescribed rates from the Public
Reference Section of the Commission, Washington, D.C. 20549
or by calling the Commission at 1-800-SEC-0330.
4
<PAGE>
In addition, Registration Statements and certain other
filings made with the Commission through its Electronic Data
Gathering Analysis and Retrieval System ("EDGAR") and
publicly available through the Commission's website located
at HTTP://www.sec.gov.
5
